LGI1 / ATTO 655 / S283-7
LGI1 / ATTO 655 / S283-7
Product Details
Supplier | Biorbyt | |
---|---|---|
Catalog #: | orb150844-100ug (View supplier product page) | |
Size | 100 μg | |
Price | $575.00 | |
Antigen | LGI1 | |
Clone | S283-7 | |
Host | Mouse | |
Isotype | IgG2a | |
Conjugate | ATTO 655 | |
Target Species | Human, Rat | |
Applications | WB, IHC-P, IF, ICC | |
Description | Mouse monoclonal to LGI1 (ATTO 655). The leucine-rich, glioma inactivated gene 1 (LGI1) was first identified as a candidate tumor suppressor gene for glioma and may play a role in other cancers. LGI1 is a member of a family of highly related proteins containing leucine-rich repeats (LRRs) which are highly similar to other transmembrane signaling molecules and receptors. LGI1 serves as a ligand to ADAM22, a metalloprotease localized at the synapse. Mutations in LGI1 account for nearly half of autodominant lateral temporal epilepsy (ADTLE), an epileptic syndrome characterized by focal seizures with predominant auditory symptoms. Two isoforms of LGI1 are known to exist; this LGI1 antibody will recognize only the longer form.. |
About LGI1 and ATTO 655
LGI1 | This gene encodes a member of the secreted leucine-rich repeat (LRR) superfamily and shares homology with members of the SLIT protein family. The encoded protein may regulate the activity of voltage-gated potassium channels and may be involved in neuronal growth regulation and cell survival. This gene is rearranged as a result of translocations in glioblastoma cell lines, and it is frequently down-regulated or rearranged in malignant gliomas. Mutations in this gene result in autosomal dominant lateral temporal epilepsy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2015] | |
---|---|---|
ATTO 655 | ATTO 655 from ATTO-Tec Gmbh has an excitation peak at 663 nm and an emission peak at 684 nm. |
Citations
Reviews & Ratings
ATTO 655 Excitation and Emission Spectra
$575.00
Supplier Page
Supplier Page